Cholangiocarcinoma Epidemiology Forecast to 2030

Cholangiocarcinoma (CCA) also known as Biliary Tract Cancer is a rare and heterogeneous malignant neoplasm with epithelial cell origin of the biliary duct and histologic and biochemical features of cholangiocyte differentiation.  The malignant tumour may arise from any portion of the bile duct i.e., from terminal ductules (canals of Hering) to the ampulla of Vater, as well as at the peribiliary glands (intramural and extramural) and sometimes may affect gallbladder.


Request for Sample Pages:


DelveInsight’s ‘Cholangiocarcinoma Epidemiology Forecast to 2030‘ report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

The DelveInsight Cholangiocarcinoma epidemiology report gives a thorough understanding of the Cholangiocarcinoma by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Cholangiocarcinoma in the US, Europe, and Japan. The report covers the detailed information of the Cholangiocarcinoma epidemiology scenario in seven major countries (US, EU5, and Japan).


Key Highlights Of The Report

  • As per the study conducted by N Patel et al., the overall incidence of Cholangiocarcinoma from 2001 to 2015 was 1.26 per 100,000 people per year in the US. Males account for higher incidence with 50.9% cases while 49.1% of cases belong to females in that study. The incidence has been shown to increase in all subpopulations and specifically at a dramatic rate for ICCA and those with the distant disease at the time of diagnosis.
  • Among the EU5 countries, Germany had the highest incident population of Cholangiocarcinoma (CCA), followed by Italy and the United Kingdom.
  • In Italy, CCA incidence was recorded to be 3.36/100,000, and CCAs accounted for approximately 3% of total primitive liver cancers. (B. Maria et al.)
  • The Japanese population has relatively higher rates of CCA incidence (Hiroshima 3.05/100,000, Osaka 3.4/100,000) as compared to other Asian countries.


Cholangiocarcinoma Epidemiology

  • Delveinsight’s Cholangiocarcinoma epidemiology division provides insights about historical and current patient pool and forecasted trends for every seven major countries. 
  • The Cholangiocarcinoma epidemiology data are studied through all possible divisions to give a better understanding of the Disease scenario in 7MM. 
  • The Cholangiocarcinoma epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. 
  • It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.


Scope of the Report

  • The report provides insight into the historical and forecasted patient pool of Cholangiocarcinoma in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of Cholangiocarcinoma.
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
  • The Cholangiocarcinoma report provides a detailed overview explaining Cholangiocarcinoma causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns.
  • The Cholangiocarcinoma Epidemiology Report and Model provide an overview of the risk factors and global trends of Cholangiocarcinoma in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan).
  • The report provides the segmentation of the Cholangiocarcinoma epidemiology. 


Key Benefit of Cholangiocarcinoma Epidemiology Report 

The Cholangiocarcinoma Epidemiology report will allow the user to –

  • Develop business strategies by understanding the trends shaping and driving the global Cholangiocarcinoma market
  • Quantify patient populations in the global Cholangiocarcinoma market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Cholangiocarcinoma therapeutics in each of the markets covered
  • Understand the magnitude of Cholangiocarcinoma population by its epidemiology
  • The Cholangiocarcinoma Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources


Request for Sample Pages:


Table of Contents

  1. Key Insights 
  2. Executive Summary of Cholangiocarcinoma
  3. Cholangiocarcinoma Disease Background and Overview
  4. Cholangiocarcinoma Patient Journey
  5. Cholangiocarcinoma Epidemiology and Patient Population
  6. Cholangiocarcinoma Treatment Algorithm, Current Treatment, and Medical Practices
  7. KOL Views on Cholangiocarcinoma 
  8. Cholangiocarcinoma Unmet Needs
  9. Appendix
  10. DelveInsight Capabilities
  11. Disclaimer

*The table of contents is not exhaustive; will be provided in the final report


About  DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.


Related Reports

Cholangiocarcinoma (CCA) – Pipeline Insights, 2020

Cholangiocarcinoma (CCA) Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Cholangiocarcinoma (CCA) market.


Cholangiocarcinoma (CCA) Market Insight, Epidemiology and Market Forecast 2030

DelveInsight’ s Cholangiocarcinoma (CCA) – Market Insights, Epidemiology and Market Forecast – 2030 report provides the detailed overview of the disease and in depth understanding of historical and forecasted epidemiology.


Contact us:

Shruti Thakur

[email protected]